In Vivo Models for the Evaluation of Antithrombotics and Thrombolytics
In Vivo Models for the Evaluation of Antithrombotics and Thrombolytics
复制标题
DOI：
10.1007/978-1-60761-803-4_2
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Mousa, Shaker A.
中科院分区：
文献类型：
--
作者：
Mousa, Shaker A.
血栓动物模型的开发和应用在新药物靶点的发现和验证以及临床评价新药物的选择中发挥了至关重要的作用，并为临床试验提供了剂量和安全性信息。这些模型还提供了有关新型抗血栓药物的作用/相互作用机制的有价值的信息。描述了血栓形成的小型和大型动物模型及其在新药发现和开发中的作用。重点介绍了有关使用血栓形成动物模型的方法和主要问题，例如阳性对照、适当的药效活性标记物、安全性评估、物种特异性和药代动力学。最后，介绍了血栓/止血遗传模型的使用以及这些模型如何帮助开发目前正在临床评估的疗法。
The development and application of animal models of thrombosis have played a crucial role in the discovery and validation of novel drug targets and the selection of new agents for clinical evaluation, and have informed dosing and safety information for clinical trials. These models also provide valuable information about the mechanisms of action/interaction of new antithrombotic agents. Small and large animal models of thrombosis and their role in the discovery and development of novel agents are described. Methods and major issues regarding the use of animal models of thrombosis, such as positive controls, appropriate pharmacodynamic markers of activity, safety evaluation, species specificity, and pharmacokinetics, are highlighted. Finally, the use of genetic models of thrombosis/hemostasis and how these models have aided in the development of therapies that are presently being evaluated clinically are presented.